Gyre Therapeutics, Inc. GYRE Fair Value Adjustment Of Warrants
Fair Value Adjustment Of Warrants at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FairValueAdjustmentOfWarrants.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s fair value adjustment of warrants.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s fair value adjustment of warrants?
- Gyre Therapeutics, Inc. (GYRE) reported fair value adjustment of warrants of -$89K in Q1 2026.
- How has Gyre Therapeutics, Inc.'s fair value adjustment of warrants changed year-over-year?
- Gyre Therapeutics, Inc.'s fair value adjustment of warrants increased by 96.1% year-over-year, from -$2.26M to -$89K.
- What is the long-term trend for Gyre Therapeutics, Inc.'s fair value adjustment of warrants?
- Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s fair value adjustment of warrants has grown at a -45.9% compound annual growth rate (CAGR), from $9.26M to -$2.71M.
- What does fair value adjustment of warrants mean?
- Represents the non-cash adjustment to the carrying value of outstanding warrants based on changes in their fair market value. This metric is significant for companies with complex capital structures involving equity-linked instruments. It reflects the impact of market price volatility on the company's potential future equity dilution.